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Abstract
The extra domain A (EDA)-containing fibronectin (EDA-FN), an alternatively spliced form of the extracellular matrix protein
fibronectin, is predominantly expressed in various malignancies but not in normal tissues. In the present study, we
investigated the potential pro-lymphangiogenesis effects of extra domain A (EDA)-mediated vascular endothelial growth
factor-C (VEGF-C) secretion in colorectal carcinoma (CRC). We detected the expressions of EDA and VEGF-C in 52 human
colorectal tumor tissues and their surrounding mucosae by immunohistochemical analysis, and further tested the
correlation between the expressions of these two proteins in aforementioned CRC tissues. Both EDA and VEGF-C were
abundantly expressed in the specimens of human CRC tissues. And VEGF-C was associated with increased expression of EDA
in human CRC according to linear regression analysis. Besides, EDA expression was significantly correlated with lymph node
metastasis, tumor differentiation and clinical stage by clinicopathological analysis of tissue microarrays containing tumor
tissues of 115 CRC patients. Then, human CRC cell SW480 was transfected with lentivectors to elicit expression of shRNA
against EDA (shRNA-EDA), and SW620 was transfected with a lentiviral vector to overexpress EDA (pGC-FU-EDA),
respectively. We confirmed that VEGF-C was upregulated in EDA-overexpressed cells, and downregulated in shRNA-EDA
cells. Moreover, a PI3K-dependent signaling pathway was found to be involved in EDA-mediated VEGF-C secretion. The in
vivo result demonstrated that EDA could promote tumor growth and tumor-induced lymphangiogenesis in mouse
xenograft models. Our findings provide evidence that EDA could play a role in tumor-induced lymphangiogenesis via
upregulating autocrine secretion of VEGF-C in colorectal cancer, which is associated with the PI3K/Akt-dependent pathway.
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Introduction
Colorectal cancer (CRC) is the fourth most common malig-
nancy worldwide with characteristic early metastasis. Lymphan-
giogenesis, associated with tumor metastasis, is evaluated in
various tumor types, such as colon malignancies [1], esophageal
carcinoma [2] and breast cancer [3]. Vascular endothelial growth
factor (VEGF)-C is a most potent lymphangiogenic factor [4],
which is correlated with lymph node metastasis in several tumors
including CRC [5,6]. Mechanically, the binding of VEGF-C to its
receptor VEGFR-3 which is expressed on human lymphatic
endothelial cells (LECs) can promote proliferation of lymphatic
vessels [7,8]. Thus, upregulation of VEGF-C production has been
implicated in induction of tumor lymphangiogenesis and lym-
phatic invasion [9].
The understanding of the formation and the proliferation of
new lymphatic vessels has been renewed by the discovery of
tumor-induced lymphangiogenesis [10]. These concepts point out
that tumors can express VEGF-C which upregulates VEGFR-3
expression of LECs and increases the number of lymphatic vessels
in the vicinity of tumors [11]. Interestingly, lymphatic vessels
surrounding VEGF-C-overexpressed tumors are multiplicated and
grow intratumoraly from the border of tumors [12]. Many studies
have reported that intratumoral lymphatics are present in several
human tumors, which is sufficient to promote lymphatic metastasis
[13].
It has been reported that VEGF-C is not only expressed in
endothelial cells, but also expressed in non-endothelial cell types,
including immune cells and cancer cells [14,15]. Researchers have
found that VEGF-C is overexpressed in various tumors including
non-small-cell lung cancer (NSCLC), oral squamous cell cancer,
undifferentiated gastric carcinoma, breast cancer, pancreatic
cancer and colorectal carcinoma [15]. Although it is clear from
many reports that overexpression of VEGF-C in a variety of
human tumors correlates with tumor-induced lymphangiogenesis,
it is less clear at what factors during tumor progression stimulate
tumors to secret these lymphangiogenic factors.
Fibronectin (FN), which is an extracellular matrix cell-adhesive
glycoprotein, contains three alternative splicing domains, extra
domain A (EDA), extra domain B (EDB) and IIICS [16,17]. It has
been reported that EDA is highly expressed in various malignan-
cies but not in normal tissues [18,19]. Our laboratory have
previously observed that EDA could facilitate growth and
tubulogenesis of LECs in the periphery of tumors [20], which
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35378indicated that EDA could contribute to tumor-associated lym-
phangiogenesis, but the underlying mechanisms remained to be
defined. In this study, we found that upregulation of EDA in
colorectal cancer cells could increase tumor cells autocrine
secretion of VEGF-C both in vitro and in vivo, and then we
explored the potential activation of intracellular signaling path-
ways. The results suggested that EDA could promote the secretion
of VEGF-C in colorectal cancer cells, and this process was
associated with the PI3K/Akt pathway.
Results
Expression and Correlation of EDA and VEGF-C in Human
Colorectal Cancer Tissues
To investigate the expression status of EDA and VEGF-C in
colorectal cancer, we examined the expression of EDA and
VEGF-C in human colorectal carcinoma samples and normal
colorectal mucosae from 52 cases of CRC patients by immuno-
histochemical staining (IHC). The positive staining of EDA was
indicated as yellow-brown precipitates in the cytoplasm in
colorectal adenocarcinoma (Fig. 1B, 1C), but no positive staining
has been seen in the adjacent normal non-cancerous colorectal
tissues (Fig. 1A). Expression of VEGF-C in colorectal cancer
tissues and cancer stroma was stained brown in the cytoplasm
(Fig. 1E, 1F). In contrast, very little or no staining of VEGF-C was
observed in normal mucosae (Fig. 1D). We further analyzed the
correlation between EDA and VEGF-C expression in individual
samples from 52 cases of CRC patients and found that EDA was
significantly positively correlated with VEGF-C (p = 0.00012)
(Fig. 1G). Then, immunohistochemistry was performed to detect
the expression of EDA protein in tissue microarrays containing
tumor samples from 115 CRC patients. The immunostaining of
EDA protein was substantially stronger in CRCs of clinically
advanced stages (III and IV) or pathologically low grades (poorly
and non-differentiated) relative to early stages (I and II) or high
grades (well and moderately differentiated) (Fig. 1H). EDA was
also highly expressed in tumor tissues of CRC patients with
lymphatic metastasis compared with patients without lymphatic
metastasis. The correlation of EDA expression with clinicopath-
ological parameters of patients is shown in Table 1. High EDA
expression was significantly correlated with present of lymph node
invasion, tumor differentiation degree and advanced clinical stage
(p , 0.05). The patient gender and age were not correlated with
EDA expression (p . 0.05).
Detection of Cellular and Secreted VEGF-C Protein in
Transfected Cells and Control Cells
In different types of human colorectal cancer cells, SW620
presents the lowest mRNA and protein level of EDA (data not
shown), while SW480 expresses the highest (previously described
in [20]). Thus, we generated pGC-FU-EDA cells (SW620 was
transfected with a lentiviral vector to overexpress EDA) for
comparison with nontransfected SW620 cells. SW480 was
transfected with lentivectors to elicit expression of shRNA against
EDA (shRNA-EDA). The transfection efficiency was observed to
be approximately 70,90% both in EDA-overexpressed cell group
and shRNA-EDA cell group under the fluorescent microscopy
(Fig. 2A). Then, we assessed the protein level of EDA and VEGF-
C in transfected cells and control cells with Western blotting
analysis (Fig. 2B). Compared with control counterparts, pGC-FU-
EDA SW620 cells showed significantly increased expression levels
of EDA and VEGF-C protein. In contrast, shRNA-EDA SW480
cells showed largely declined expression levels of EDA and VEGF-
C protein.
ELISA test was performed to analyze the secretion of VEGF-C.
The secretion of VEGF-C was largely increased in EDA-
overexpressed cells supernatant compared with the control group
(Fig. 2D, p , 0.01). Conversely, VEGF-C protein production was
decreased in shRNA-EDA SW480 supernatant (Fig. 2C, p ,
0.01). There was no obvious difference between the mock
lentivector transfected tumor cells and nontransfected tumor cells.
Effect of EDA on the PI3K/Akt Signaling Pathway of
Colorectal Cancer Cells
PI3K/Akt pathway activation is known to mediate signal
transduction of several growth factors. It has been reported that
type I insulin-like growth factor receptor (IGF-IR) induces VEGF-
C expression in an Akt-dependent pathway [21]. Thus, to
investigate how EDA regulates VEGF-C, we checked the
expression of phosphorylated Akt in the transfected group and
the control group. Western blotting analysis showed that the
increased level of phosphorylated Akt was detected in pGC-FU-
EDA SW620 cells, while the expression of p-Akt in shRNA-EDA
SW480 cells was decreased significantly. There was no significant
difference between mock lentivector transfected tumor cells and
nontransfected tumor cells (Fig. 3A, 3B). To identify the PI3K/Akt
signaling pathway involved in EDA-mediated induction of VEGF-
C, we examined the effect of PI3-Kinase specific inhibitor
(LY294002). Dose-dependent reductions of VEGF-C expression
were observed when the EDA-overexpressed cells were cultured
with 0 mM, 5 mM, 10 mM, or 20 mM LY294002 in the absence of
FBS for 24 h (Fig. 3C). LY294002 (0–20 mM) significantly reduced
the levels of phosphorylated Akt in EDA-overexpressed cells in
a concentration-dependent manner, but the levels of total Akt
were not changed (Fig. 3C). PI3K/Akt signaling pathway
activation thus might play a role in the EDA-mediated VEGF-C
secretion.
The Tumorigenicity and Expression of EDA and VEGF-C in
Nude Mouse Xenograft Models of Colorectal Carcinoma
We established nude mouse xenograft models in which pGC-
FU-EDA SW620 cells, shRNA-EDA SW480 cells and control cells
were subcutaneously injected in the left inguina. The solid tumors
became directly visible by gross examination 2 weeks after
implantation. Tumor sizes were detected by measuring with
vernier caliper after 6 weeks of tumor growth (data shown in
Fig. 4B, p , 0.05). Autopsy analysis showed that the xenografts
derived form pGC-FU-EDA SW620 cells were grown bigger than
those developed from SW620 cells or mock group as measured by
tumor weight and volume (Fig. 4A). In contrast, the subcutaneous
tumors developed from shRNA-EDA SW480 cells were grown
distinctly smaller than those in the control group (Fig. 4A).
Immunohistochemical staining revealed that the staining in-
tensity of EDA and VEGF-C in pGC-FU-EDA SW620 tumor
group was enhanced in comparison with that in nontransfected
control group or mock lentivector transfected group, and the
staining intensity in shRNA-EDA SW480 tumor group was
extremely diminished in comparison with that in the control
group (Fig. 4C).
The Tumorigenicity of Human CRC in an Orthotopic
Nude Mouse Model and Effect of EDA on Intratumoral
Lymphangiogenesis in Vivo
pGC-FU-EDA SW620 cells, shRNA-EDA SW480 cells and
control cells were implanted orthotopically into nude mice to
analyze their tumorigenic potential. All cell lines formed tumors
8 weeks after implantation. Tumors formed by pGC-FU-EDA
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nontransfected control cells or mock lentivector transfected cells,
while tumors formed by shRNA-EDA SW480 cells were the
smallest and grew more slowly than those control group cells
(Fig. 5A).
To investigate whether EDA upregulating the secretion of
VEGF-C can contribute to intratumoral lymphangiogenesis in vivo,
we examined the number of intratumoral lymphatic vessels by
immunohistochemistry analysis. The results showed that there was
a higher LMVD in pGC-FU-EDA SW620 tumor group as
compared with that in control group (Fig. 5B). However, an
extremely small number of intratumoral lymphatic vessels were
found in shRNA-EDA SW480 tumor group (Fig. 5B). Right panel
shows the quantification data about the lymph microvessel density
(LMVD) (Fig. 5C, p , 0.01).
Discussion
Lymphangiogenesis or the growth of lymphatic vessels is an
important step in tumor metastasis. Lymphangiogenesis and
early regional metastasis frequently occurs in several kinds of
malignant tumors including colorectal cancer. Metastasis to
regional lymph nodes is generally believed as the first indication
that a tumor has progressed to metastatic competence.
However, many studies have cast new light on the biology of
lymphangiogenesis and molecular mechanisms of tumor regional
lymph nodes metastasis. One of the mechanisms is tumor-
induced lymphangiogenesis. Evidences of intratumoral lymphatic
vessels raise the possibility that tumor cells can contribute to
lymphatic metastasis through the induction of a lymphangiogenic
process [22]. It is well known that tumor cells enter the
Figure 1. Immunohistochemical staining for EDA and VEGF-C in human colorectal carcinoma. Representative images of EDA expression
in human colorectal carcinoma tissues (B) and in normal colorectal mucosae (A) are shown. Representative images of VEGF-C expression in colorectal
carcinoma tissues (E) and in normal mucosae (D) are shown. Inset shows higher magnification of EDA(C) and VEGF-C (F) staining (brown), distinct
from the colorectal benign mucosa. (G) Linear regression of EDA and VEGF-C of 52 human colorectal cancer samples was performed. (H)
Representative images of EDA expression in tissue microarrays containing tumor samples from 115 CRC patients are shown. The bottom panel shows
higher magnification of EDA staining. The slides were counterstained with hematoxylin. Scale bar=50 mm.
doi:10.1371/journal.pone.0035378.g001
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Variables Total Number of patients (%) Chi-square test
EDA low expression EDA high expression P value
Age (year)
,61 49 15 (30.6) 34 (69.4) 0.092
a
$61 66 14 (21.2) 52 (78.8)
Gender
Male 64 19 (29.7) 45 (70.3) 0.078
a
Female 51 10 (19.6) 41 (80.4)
Lymph node metastasis
Present 44 6 (13.6) 38 (86.4) 0.014
a
Absent 71 23 (32.4) 48 (67.6)
Grade
well and moderately differentiated 85 25 (29.4) 60 (70.6) 0.041
b
poorly and non-differentiated 30 4 (13.3) 26 (86.7)
Clinical stage
early stage 65 21 (32.3) 44 (67.7) 0.026
a
advanced stage 50 8 (16.0) 42 (84.0)
doi:10.1371/journal.pone.0035378.t001
Figure 2. Expression of cellular and secreted VEGF-C protein in transfected cells and control cells. (A) shRNA-EDA SW480, mock SW480,
pGC-FU-EDA SW620 and mock SW620 were confirmed by uorescent microscopy. (B) Expression of EDA and VEGF-C protein was determined by
western blotting. GAPDH was a loading control. VEGF-C protein concentration in transfected SW480 group(C) and transfected SW620 group (D) was
detected by ELISA. This experiment was repeated in duplicate more than three times. The error bars are the means 6 SEM. and ** p , 0.01 is
considered as statistically significant. Scale bar =50 mm.
doi:10.1371/journal.pone.0035378.g002
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factor production. Moreover, lymphangiogenic growth factors
produced by tumor cells stimulate growth and dilation of the
tumor-induced lymphatic vessels, as well as facilitating tumor
regional lymph nodes metastasis. VEGF-C, as one of the
lymphangiogenic growth factors, is a key regulator in lymphan-
giogenesis and tumor metastasis [23]. Early studies suggested
that VEGF-C could promote the growth of new lymphatic
vessels and regional metastasis by binding to their receptor
tyrosine kinase VEGFR-3 which was expressed abundantly in
lymphatic endothelial cells [24,25]. Studies with human or
animal tumor models implicated that malignant tumor cells
themselves could secrete high levels of VEGF-C [26], and this
overexpression of tumor-derived VEGF-C might play an
important role in intratumorally-occurred lymphangiogenesis,
which would in turn promote dissemination of tumor cells to
regional lymph nodes [27–29].
Thestimulationbymanygrowthfactors,includingIGF-1,PDGF,
EGF,andTGF-b,hasbeenshowntoinducetheexpressionofVEGF-
Cinmalignanttumors[30].Inourpreviousstudy,weinvestigatedthe
fibronectin alternatively spliced EDA domain and its effects on
lymphatic neovasculature of colorectal carcinoma [20]. We found
that EDA promoted cytoskeleton organization and tubulogenesis
capability of LECs. These results suggested that EDA could be
regardedasapromisingfactoroftumor-associated lymphangiogen-
esis.Butasystematicstudyofthisfactoronthemolecularmechanisms
of lymphangiogenesis has not been conducted. In this study, we
wantedtoinvestigatethepossibleregulationmechanismsofEDAto
the growth oflymphatic vessels.
According to our work, we hypothesized that EDA stimulates
lymphangiogenesisthroughthefollowingtwopotentialmechanisms:
(1)directstimulationofLECsgrowth;and(2)stimulationofautocrine
secretion of VEGF-C by tumor cells themselves. As for the first
mechanism,combinedwiththefactthatintegrina9b1isastructurally
related receptor of EDA [31] and our previous study in which we
foundthatintegrina9wasupregulatedwhenLECsweretreatedwith
theexogenousEDA,aconclusioncouldbedrawnthatEDA-induced
lymphangiogenesismightpartlydependontheactivationofintegrin
a9ofLECs.WepresumedtheotherpotentialmechanismisthatEDA
may stimulate tumor-induced lymphangiogenesis via upregulating
autocrinesecretionofVEGF-Cincolorectalcancercells.Itisknown
thatVEGF-CcanpromotetheproliferationofLECs.Inaddition,we
found that elevated expression of EDA significantly correlated with
the overexpression of VEGF-C in colorectal cancer tissues by
immunohistochemistryanalysis.Toinvestigatethepossibilityofthis
mechanism, we have generated EDA-overexpressed tumor cells
(pGC-FU-EDA) and shRNA-EDA tumor cells. Western blotting
analysis exhibited that EDA-overexpressed cell group was detected
increased level of EDA and VEGF-C protein. Conversely, shRNA-
EDAcellgroupexpresseddecreasedlevelofEDAandVEGF-C.By
virtueofthese,wetestedthesecretedVEGF-Cproteinintransfected
cells and control cells by ELISA. The EDA-overexpressed SW620
group had a significantly upregulated VEGF-C protein level
compared with the nontransfected SW620 group. By contrast, the
level of secreted VEGF-C was largely depressed in supernatant of
shRNA-EDA SW480 cells. All of these results implicated that EDA
could contribute tothe excretion ofVEGF-C in colorectalcancer.
To corroborate these findings further, we established nude
mouse xenograft models. Tumors formed by shRNA-EDA SW480
cells were the smallest and grew more slowly, while tumors formed
by EDA-overexpressed SW620 cells grew more rapidly after
implantation. Moreover, immunohistochemical staining showed
that both the staining intensity of VEGF-C and the number of
intratumoral lymphatic vessels in EDA-overexpressed SW620
tumor group were increased, while both of them were reduced in
shRNA-EDA SW480 tumor group. These results suggested that
EDA could facilitate tumor proliferation and VEGF-C-mediated
tumorous lymphangiogenesis. By virtue of these, we verified these
results by analyzing the relationship between EDA and clinico-
pathological parameters of CRC patients. We detected the
expression of EDA protein in tissue microarrays containing tumor
samples from 115 CRC patients and found that EDA expression
was significantly correlated with present of lymph node invasion,
tumor differentiation degree and advanced clinical stage.
Furthermore,westudiedthesignalingpathwayinvolvedinEDA-
mediated tumor-derived VEGF-C secretion. The expressional
Figure 3. Activation of PI3K/Akt signaling pathway in trans-
fected cells and control cells. (A) p-Akt and Akt proteins of SW620
group and SW480 group were performed by western blotting analysis.
(B) Quantitative analysis shows the ratio of p-Akt/GAPDH. The error bars
are standard deviations of three independent experimental results. * p
, 0.05 and ** p , 0.01 are considered statistically significant and highly
significant, respectively. (C) VEGF-C, p-Akt and Akt proteins of EDA-
overexpressed SW620 cells were performed by western blotting when
the EDA-overexpressed cells were preincubated in medium containing
0–20 mM LY294002 for 24 h. Wild type SW620 was set up as the control
group. The results shown are the average of three experiments.
doi:10.1371/journal.pone.0035378.g003
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hypoxia induces VEGF-A expression in an PI3K/Akt-dependent
pathway [32]. And PI3K/Akt signaling pathway is also involved in
IGF-1-inducedVEGF-Cexpressioninlungcarcinomacells[21].Itis
well known that PI3K can mediate the phosphorylation and
activation of its downstream serine/threonine kinase, Akt (or PKB),
participatinginsomeimportantbiologicalactivitiessuchassurvival,
proliferation, migration and differentiation in human cancer
[33].The activation of Akt also contributes to tumorigenesis and
tumor metastasis in various types of human cancer [34,35]. By
exploring well-characterized pathways known to regulate tumor-
derived VEGF-C expression, we found that PI3K/Akt signal
transduction pathway probably plays a pivotal role in the EDA-
mediated regulation of VEGF-C expression in human colorectal
carcinomas. We performed Western blot to study the activation of
PI3K/Aktsignalingpathwayintransfectedcellsandcontrolcells.In
EDA-overexpressed cells, the levels of phospho-Akt were more
activatedthannontransfectedcellsinresponsetoEDA.Additionally,
wefoundthatcellspretreatedwithPI3KspecificinhibitorLY294002
could inhibit EDA-induced Akt phosphorylation, and consequently
caused a significant inhibition of VEGF-C induction. Impressively,
theblockageoftheseintracellularsignalingcomponentsandVEGF-
C induction was concentration-dependent. These results indicate
thatthePI3K/Aktpathwayisinvolvedintheexpressionalregulation
of EDA-mediated VEGF-C incolorectalcancer cells.
In conclusion, our findings support the hypothesis that during
the process of tumor-induced lymphangiogenesis, the extra
domain A of fibronectin could promote the creation of new
lymphatic vessels and one of its mechanisms may be that EDA
could enhance VEGF-C concentration in colorectal cancer, and
the activation of the PI3K/Akt signaling pathway is involved in
this upregulation. Considering all of these, EDA and its effects on
activating intracellular signaling pathways may open novel
imaging opportunities and targeted therapeutic modalities in
dealing with lymphatic metastasis in colorectal carcinoma.
Materials and Methods
Ethics Statement
Experiments using the animals were conducted with the
approval of the Animal Care and Use Committee of Third
Military Medical University (Approval ID: SCXK (Military)
2007015), according to the State Science and Technology
Figure 4. BALB/c nude mice were subcutaneouly injected with transfected cells and negative control cells. Xenografts were excised and
sized 42 days later. (A) Effect of EDA on tumor proliferation. (B) Tumor volumes were measured when mice were sacrificed and the data are presented
as mean determinants (6SEM). * p , 0.05. (C) Immunohistochemical staining of EDA and VEGF-C was performed in nude mouse xenografts. Scale bar
=50mm.
doi:10.1371/journal.pone.0035378.g004
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cerning Experimental Animals (1988, China).
The clinical investigation was complied with the Helsinki
Declaration. The protocol of immunohistochemistry for patient
tissues was approved by the Ethics Committee of Southwest
Hospital, Third Military Medical University (Permit Number:
2009[21]), and all patients provided written consent form.
Cell Lines and Culture Conditions
The human colorectal carcinoma cell lines SW620, SW480 and
HEK293T were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cell culture reagents were
purchased from Gibco-Invitrogen (Carlsbad, CA, USA). Cells
were maintained in Dulbecco’s Modified Eagle’s Medium,
supplemented with 10% fetal bovine serum, 100 U/ml penicillin
Figure 5. Orthotopic xenografts derived from transfected cells and control cells. Seven to 8 wk old male BALB/c nude mice were
orthotopically implanted with 6 groups of tumor xenografts. (A) Representative images of xenografts. Orthotopic images of xenograft tumors derived
from 6 groups of transfected cells and control cells. Scale bar=5 mm. (B) Expression of LYVE-1 was used to count LMVD in xenografts by
immunohistochemical staining. The distribution of lymph vessels was stained brown under the light microscope. Scale bar =50 mm. (C)
Quantification of lymph microvessel density (LMVD) is shown. The results shown are the average of three experiments. ** p , 0.01, as compared with
control group. The values are displayed as the mean 6 SEM.
doi:10.1371/journal.pone.0035378.g005
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5% CO2.
Construction and Preparation of Lentivirus for RNAi and
Overexpression of EDA
shRNA-EDA (GGATGGAATCCATGAGCTA) was designed
against EDA (accession number: NM212482) and synthesized as
follows: Forward: 59- CcgggaGGATGGAATCCATGAGC-
TATTCAAGAGATAGCTCATGGATTCCATCCtcTTTTTg-
39, and Reverse: 59- aattcaaaaagaGGATGGAATCCATGAGC-
TATCTCTTGAATAGCTCATGGATTCCATCCtc-39. These
oligos were annealed and inserted downstream of the U6 promoter
on the lentiviral vector pGCL-GFP (GeneChem). A control vector
containing non-silencing sequence (59-TTCTCCGAACGTGT-
CACGT-39) was supplied by GeneChem Co., Ltd. (Shanghai,
China). For overexpression of EDA, ORF of EDA was cloned into
the lentiviral vector expression plasmid pGC-FU (GeneChem).
Lentiviruses were generated by triple transfection of 80%
confluent HEK293T cells with pGCL-GFP-shEDA or pGC-FU-
EDA plasmid, together with pHelper 1.0 and pHelper 2.0 helper
plasmids (GeneChem) using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA).
Lentivirus was harvested at 48h and 72 h post transfection,
centrifuged to remove cell debris, and then filtered through
a 0.45 mm cellulose acetate filter followed by ultracentrifugation.
For lentivirus infection, SW480 and SW620 cells were grown to
70–80% confluence and infected with pGCL-GFP-shEDA
lentivirus, pGC-FU-EDA lentivirus or control lentivirus, separate-
ly, at MOI of 10 (SW480) or 50 (SW620). To determine the
infection efficiency, cells expressing GFP protein were imaged
using laser confocal scanning microscopy (Leica TSC-SP5,
Germany) 4 days after infection. The GFP positive cells were
purified with a FACSCalibur flow cytometer (BD Biosciences).
Inhibition of Signal Transduction Kinase
EDA-overexpressed SW620 cells were seeded at a density of
1.0610
5/ml cells/well in 6-well plates and incubated in serum-free
medium overnight. LY294002 (Sigma Chemical Co., St. Louis,
MO) was dissolved in DMSO at a stock concentration of 10 mM
and added to cell cultures at a concentration of 0 mM, 5 mM,
10 mM, or 20 mM. The final concentration of DMSO used in our
study did not affect cell survival or protein phosphorylation. Cells
were treated by LY294002 for 24 h and then prepared for
Western blot.
Tissue Microarrays and Immunohistochemistry (IHC)
One hundred and fifteen colorectal cancers were made into
tissue microarrays using the tissuearrayerTMA-1(Beecher Instru-
ments, WA, USA) as described previously[36]. Fifty-two samples
including colorectal cancers and their surrounding tissues as well
as xenografts were collected and processed into formalin-fixed
paraffin-embedded tissue blocks, then cut into 4 mm-thickness
sections. The tissue microarrays and tumor sections were routinely
dewaxed in xylene, rinsed in graded ethanol, and finally
rehydrated in double-distilled water. Endogenous peroxidase
activity was blocked by incubation in 3% hydrogen peroxide-
methanol for 15min. Antigen retrieval was accomplished by
heating the slides in 1 mM EDTA solution (pH 8.0). After washing
in phosphate-buffered saline and exposure to 10% normal goat
serum for 10 min to reduce nonspecific binding, the slides were
incubated overnight at 4uC with a 1:100 dilution of goat anti-
human VEGF-C polyclonal antibody (Abcam, Cambridge, MA,
USA) or a 1:100 dilution of mouse anti-human EDA polyclonal
antibody (Santa Cruz Biotechnology, CA, USA). The tissue
microarrays and sections were stained using the SP method
according to the kit instructions. The instantaneous SP supersen-
sitive kits (PV-9003 and PV-6002) were provided by Beijing
Zhongshan Jinqiao biotechnology Co., Ltd.
Criteria for Assessing Immunohistochemical Results
For each slide, five random fields were selected for scoring and
a mean score of each slide was calculated in final analysis. Positive
staining was accessed using a five scoring system: 0 (no positive
cells), 1 (,10% positive cells), 2 (10%–40% positive cells), 3 (40%–
70% positive cells), and 4 (.70% positive cells). To achieve
accuracy, the intensity of positive staining was also used in a four
scoring system: 0 (negative staining), 1 (weak staining exhibited as
light yellow), 2 (moderate staining exhibited as yellow brown), and
3 (strong staining exhibited as brown). Protein expression index =
(intensity score) 6(positive score). To test the correlation between
EDA and VEGF-C, linear regression analysis was performed
based on expression index of each protein.
ELISA Assay
Cells were put into 25 ml culture bottles at the density of
2.0610
5/ml. After 24h in culture, supernatants of these cells were
harvested in sterile conditions respectively, centrifuged to remove
eventual dead cells. Supernatants were centrifuged at 1,200 rpm
for 5 min at 4uC. The levels of VEGF-C secretion were measured
using mouse enzyme-linked immunosorbent assay (ELISA) kits
(Shanghai Hushang Biotechnology Co., Ltd.). According to the
instructions of ELISA reagent kit, the light absorption value at
450 nm wavelength was measured with microplate reader (Bio-
Rad, Hercules, CA). The experiment was repeated three times and
each time we would use three parallel wells.
Western Blotting Analysis
Cell extracts were prepared and Western blotting were
performed according to the instruction of RIPA buffer (Biotek
Corporation, Beijing, China). Cell lysates were collected by
centrifugation at 12,000 rpm for 15 min at 4uC, and then
transferred to clean microcentrifuge tubes. Protein concentration
was determined with Bradford reagent (Bio-Rad), and equal
amounts of proteins (50 mg) were run on a 10% SDS–PAGE gel
and blotted onto polyvinylidene fluoride membranes. After
blocking for 2h at room temperature with 5% non-fat-dry milk,
membranes were incubated with anti-VEGF-C goat polyclonal
antibody, anti-EDA mouse polyclonal antibody, Akt antibody
(Cell Signaling Technology; 1/2000), phospho-Akt antibody (Cell
Signaling Technology;1/2000) and anti-GAPDH antibodies
(Santa Cruz Biotechnology) at 4uC overnight, respectively. The
secondary antibody was HRP-conjugated anti-IgG (Boster Bio-
technology, Wuhan, China). Membranes were then incubated
with SuperSignal West Femto Maximum Sensitivity Substrate
(Pierce, Rockford, IL, USA) for 1minute and imaged using a Gel
Doc XR system (Bio-Rad). Antibodies were removed with
stripping buffer (Pierce) at 50uC for 30 min, followed by washing
with PBS Tween 20, and membranes were reprobed.
Animals and Subcutaneous Implantation of Tumors
Male athymic BALB/c nude mice (4–5 weeks old) were
purchased from the Institute of Experimental Animal of Third
Military Medical University (Chongqing, China). Mice were
maintained under specific pathogen-free conditions. All animals
had free access to standard laboratory mouse food and water. Cells
(1.0610
6) in 0.1 ml PBS were injected subcutaneously into the
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randomly chosen and assigned to 6 groups (3 mice per group)
based on the difference of cells:SW620 control group, pGC-FU-
EDA SW620 group, Mock-SW620 group,SW480 control group,
shRNA-EDA SW480 group, Mock-SW480 group. Tumor growth
was monitored at a defined regular interval (5 days) by measuring
diameters using vernier caliper. Tumor volume was determined
based on the following formula: volume=0.52 ab
2, where a=long
diameter and b=short diameter. After a 42-day follow-up period,
mice were sacrificed and the tumors were removed. The tumors
were fixed in 10% buffered formalin for IHC.
Animals and Orthotopic Implantation of Tumors
Male athymic BALB/c nude mice (7–8 weeks old) were
purchased from the Institute of Experimental Animal of Third
Military Medical University (Chongqing, China). Mice were
maintained under specific pathogen-free conditions. All animals
had free access to standard laboratory mouse food and water. To
establish orthotopic xenografts, cells (1.0610
7) in 200 ml PBS were
injected into the colon subserosa of male athymic BALB/c nude
mice respectively. Mice were randomly chosen and assigned to 6
groups (5 mice per group) based on the difference of cells: SW620
control group, pGC-FU-EDA SW620 group, Mock-SW620
group, SW480 control group, shRNA-EDA SW480 group,
Mock-SW480 group. Stool shape and abdominal pertrusion in
the animals were observed every other day. Subsequently, five
mice of each group were sacrificed 8 weeks after the cancer cell
injection. Xenografts were harvested for section preparation.
Tumor volume was determined based on the following formula:
volume=0.52 ab
2, where a=long diameter and b=short di-
ameter.
Immunohistochemistry Analysis and Lymph Microvessel
Density Quantification
For immunohistochemical staining of orthotopic xenografts,
tumor tissue specimens were fixed in 10% buffered formalin. The
fixed tissues were embedded in paraffin, and serial sections were
made and stained with a 1:200 dilution of a rabbit polyclonal
antibody against LYVE-1 (Abcam, Cambridge, MA, USA) for
lymph microvessel density analysis. The sections were stained
using the SP method according to the kit instructions. Under the
light microscope, lymph microvessel density was determined by
counting the number of lymph microvessels per 3 high power
fields (x100) in the sections.
Statistical Analysis
Statistical analysis of the in vitro and in vivo results was analyzed
using SPSS 13.0 software (Version 13.0, LEAD Technologies,
Chicago, USA). To compare the statistical significance of
differential findings among different experimental groups, one-
way analysis of variance (ANOVA) was performed. The
quantitative data were expressed as the mean 6 SEM of three
to five independent experiments. p values below 0.05 (*) and 0.01
(**) were considered statistically significant and highly significant,
respectively.
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